opgen
announces
successful
completion
study
collaboration
karolinska
institutet
bacterial
pneumonia
patients
presents
data
unyvero
hpn
panel
eccvid
rapid
accurate
detection
essential
assess
bacterial
pneumonia
critically
ill
patients
unyvero
hpn
panel
demonstrated
high
negative
predictive
value
potentially
high
clinical
utility
rapid
unyvero
reduces
diagnostic
turnaround
times
days
less
hours
hpn
panel
viewed
useful
diagnostic
tool
help
early
detection
antimicrobial
stewardship
gaithersburg
md
holzgerlingen
germany
globe
newswire
opgen
nasdaq
opgn
opgen
precision
medicine
company
harnessing
power
molecular
diagnostics
bioinformatics
help
combat
infectious
disease
announced
today
successful
completion
clinical
study
subsidiary
curetis
gmbh
karolinska
institutet
stockholm
sweden
collaboration
set
identify
bacterial
hospitalized
patients
pneumonia
patients
study
admitted
icu
respiratory
deterioration
hospital
stay
lower
respiratory
tract
samples
analyzed
unyvero
hpn
panel
data
study
presented
escmid
conference
coronavirus
disease
eccvid
september
demonstrated
several
advantages
unyvero
hpn
panel
including
ability
identify
clinically
important
pathogens
staphylococcus
aureus
pseudomonas
aeruginosa
stenotrophomonas
maltophilia
haemophilus
influenzae
among
several
others
missed
microbiological
methods
study
also
demonstrated
reliable
performance
potentially
high
clinical
utility
unyvero
hpn
panel
rapid
diagnostic
tool
based
high
negative
predictive
value
observed
study
average
turnaround
time
final
culture
result
hours
patients
continued
receive
empiric
antibiotics
unyvero
hpn
panel
reduced
turnaround
times
days
less
hours
believe
rapid
accurate
detection
essential
assess
bacterial
pneumonia
critically
ill
patients
study
investigators
concluded
unyvero
hpn
panel
useful
diagnostic
tool
help
early
detection
lower
respiratory
tract
infections
antimicrobial
stewardship
patients
suspected
antimicrobial
resistance
amr
panel
beneficial
escalation
antibiotics
study
tested
samples
obtained
subjects
consisting
tracheal
secretions
bronchoalveolar
lavage
protected
specimen
brush
psb
bronchial
secretions
sputum
sample
one
sample
obtained
unique
subjects
two
samples
subjects
three
samples
subjects
mean
age
among
study
subjects
years
old
male
female
diagnosis
management
severe
challenging
signs
symptoms
similar
bacterial
pneumonia
furthermore
infection
especially
hospitalized
patients
gaining
recognition
predisposing
factor
secondary
bacterial
pneumonia
therefore
believe
important
accurately
distinguish
correct
etiology
treat
appropriately
example
estimated
patients
treated
empirically
antibiotics
despite
fact
caused
virus
comes
managing
bacterial
pneumonia
patients
time
critical
pleased
share
data
highlights
clinical
utility
unyvero
hpn
panel
providing
comprehensive
diagnostic
information
clinicians
hours
minutes
actual
time
ensuring
faster
treatment
decisions
supporting
antimicrobial
stewardship
efforts
said
faranak
atrzadeh
chief
scientific
affairs
marketing
officer
opgen
patients
especially
intensive
care
units
ventilation
many
may
elderly
preexisting
conditions
compromise
immune
system
higher
risk
acquiring
bacterial
pose
severe
complications
always
easily
determined
based
clinical
symptoms
alone
rapid
detection
bacterial
etiology
causing
pneumonia
among
patients
unyvero
hpn
panel
helpful
early
initiation
targeted
antimicrobial
unyvero
hospitalized
pneumonia
hpn
panel
detects
clinically
relevant
pathogens
antibiotic
resistance
markers
less
five
hours
directly
native
specimen
around
two
minutes
time
compared
routine
bacterial
cultures
take
several
days
confirmatory
pathogen
identification
antimicrobial
susceptibility
testing
results
unyvero
lrt
lrt
bal
panels
rapid
detection
lower
respiratory
tract
infections
pneumonia
tracheal
aspirate
samples
bronchoalveolar
lavage
fluids
respectively
unyvero
hpn
lrt
bal
syndromic
pneumonia
panels
also
include
pneumocystis
jirovecii
key
fungal
pathogen
often
found
immunocompromised
patients
difficult
diagnose
opgen
opgen
gaithersburg
md
usa
precision
medicine
company
harnessing
power
molecular
diagnostics
bioinformatics
help
combat
infectious
disease
along
subsidiaries
curetis
gmbh
ares
genetics
gmbh
developing
commercializing
molecular
microbiology
solutions
helping
guide
clinicians
rapid
actionable
information
life
threatening
infections
improve
patient
outcomes
decrease
spread
infections
caused
microorganisms
mdros
opgen
product
portfolio
includes
unyvero
acuitas
amr
gene
panel
lighthouse
ares
technology
platform
including
aresdb
using
ngs
technology
bioinformatics
solutions
antibiotic
response
prediction
information
please
visit
statements
press
release
includes
statements
regarding
performance
characteristics
potential
clinical
impact
antibiotic
therapy
regimen
clinical
utility
opgen
unyvero
hpn
lrt
lrt
bal
cartridges
statements
statements
regarding
opgen
unyvero
products
commercialization
launch
future
plans
goals
constitute
statements
within
meaning
section
securities
act
section
securities
exchange
act
intended
qualify
safe
harbor
liability
established
private
securities
litigation
reform
act
statements
subject
risks
uncertainties
often
difficult
predict
beyond
control
may
cause
results
differ
materially
expectations
factors
could
cause
results
differ
materially
described
include
limited
ability
successfully
timely
develop
seek
obtain
regulatory
clearance
commercialize
product
services
offerings
rate
adoption
products
services
hospitals
healthcare
providers
success
commercialization
efforts
impact
company
operations
financial
results
commercialization
efforts
well
capital
markets
general
economic
conditions
realization
expected
benefits
business
combination
transaction
curetis
gmbh
effect
business
existing
new
regulatory
requirements
economic
competitive
factors
discussion
significant
risks
uncertainties
associated
opgen
business
please
review
filings
securities
exchange
commission
cautioned
place
undue
reliance
statements
based
expectations
date
press
release
speak
date
press
release
undertake
obligation
publicly
update
revise
statement
whether
result
new
information
future
events
otherwise
opgen
contact
oliver
schacht
ceo
investorrelations
press
contact
matthew
bretzius
fischtank
marketing
pr
matt
investor
contact
megan
paul
edison
group
mpaul
